Cryo-Cell International heads into the final days of April with an unusual short-interest spike that looks more like noise than a structural shift — but it is worth understanding why.
Short interest nearly doubled over the week to April 28, jumping 85% from roughly 6,400 to 11,800 shares. In absolute terms, that sounds dramatic. In float terms, it barely registers: those 11,800 shares represent just 0.28% of the free float, up from about 0.15% a week earlier. The stock is a micro-cap with a market value around $28 million and a very thinly traded float. At the official FINRA settlement for mid-April, shorts held 7,936 shares with less than one day to cover. The story here is not a crowded short position — it is a micro-float name where tiny position changes produce large percentage swings.
The lending market confirms there is no real pressure building. Availability remains ample, with utilization running at just 2.68% — well below even its 52-week high of 7.33%. Cost to borrow ticked up 6% on the week to 0.84%, but that follows a longer downward trend, with the rate more than 31% lower than a month ago. These are not the conditions that precede a squeeze. The borrow pool is loosely held, and demand from shorts remains negligible.
The ORTEX short score of 27.4, while ranking in the 89th percentile of its sector on the short-score rank factor, reflects relative positioning within a low-activity universe rather than outright aggressive shorting. Days to cover is under half a day. There is no meaningful directional bet here from the short side.
Ownership is concentrated and worth noting. Chairman and CEO David Portnoy controls roughly 19% of shares. His brother Mark holds another 12%. Together, the two Portnoy insiders account for nearly a third of the company's shares. With so much of the float locked up by insiders, it is unsurprising that even small changes in borrow demand produce outsized percentage moves in the short-interest figures. The most recent insider activity on record — a cluster of CEO purchases in November 2025 at prices around $4.04–$4.13 — shows buying activity well above the current $3.52 close. That data is now around five months old and should be treated as historical context rather than a current signal.
Camac Partners, LLC is the one institutional name worth flagging. The fund disclosed a fresh 430,900-share position as recently as March 25, representing 5.35% of shares outstanding — a meaningful stake in a company this small. Vanguard added 33,879 shares through to March 31. Neither move is large in dollar terms, but in a name with a total of 22 known institutional holders, any institutional entry draws attention.
Q1 results are due July 10. The last four earnings prints produced muted 1-day reactions — moves ranging from -3.8% to +3.1% — before giving back gains over the following five sessions in two of the four cases. With the stock up 6.3% over the past month but down fractionally on the week to $3.52, the setup into summer is quiet. The short-score trajectory and borrow dynamics are worth revisiting if utilization accelerates or availability tightens materially ahead of that July date.
See the live data behind this article on ORTEX.
Open CCEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
